Nuclear Medicine Innovation2

[WP-29-7] Preclinical safety of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer

Hiroki Matsumoto^1,2、Tadashi Watabe³、Chika Igarashi^1,2、Tomoko Tachibana¹、Fukiko Hhara¹、Hiroaki Kurihara²、Makoto Ueno²、Kimiteru Ito⁴、Tatsuya Higashi¹、Yukie Yoshii^1,2 (1.National Institutes for Quantum Science and Technology、2.Kanagawa Cancer Center、3.Osaka University Graduate School of Medicine、4.National Cancer Center Hospital)